Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.65 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.65 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006814 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1005572 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1006544 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1008290 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007485 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1008153 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1008879 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1006839 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007208 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007446 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-1945705-B1 | PHOTOLATENT SYSTEMS | BASF SE (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-7820865-B2 | Photolatent systems | CIBA CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090162307-A1 | Photolatent Systems | CIBA CORP. | 2009-06-25 | — | — | US | disclosed |
| EP-1945705-A1 | PHOTOLATENT SYSTEMS | Ciba Holding Inc. (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054446-A1 | PHOTOLATENT SYSTEMS | CIBA HOLDING INC. (CH) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162307-A1 | Photolatent Systems | CCNT1, CCNT2, C1S | LCK 4749/4885PPARD 1066/4885ZDHHC20 2150/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | LCK 4877/4885PPARD 3616/4885ZDHHC20 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.